Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Parfrey

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
The New England Journal of Medicine|September 17, 2010
Erythropoietic response and outcomes in kidney disease and type 2 diabetesScott D Solomon, Hajime Uno, Eldrin F Lewis, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2003
Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney diseaseRiccardo Magistroni, Ning He, Kairong Wang, et al.
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2010
Genetic variation of DKK3 may modify renal disease severity in ADPKDMichelle Liu, Sally Shi, Sean Senthilnathan, et al.
Journal of the National Cancer Institute|March 9, 2010
Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability statusPeter T Campbell, Elizabeth T Jacobs, Cornelia M Ulrich, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
The New England Journal of Medicine|September 17, 2010
Erythropoietic response and outcomes in kidney disease and type 2 diabetesScott D Solomon, Hajime Uno, Eldrin F Lewis, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2003
Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney diseaseRiccardo Magistroni, Ning He, Kairong Wang, et al.
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2010
Genetic variation of DKK3 may modify renal disease severity in ADPKDMichelle Liu, Sally Shi, Sean Senthilnathan, et al.
Journal of the National Cancer Institute|March 9, 2010
Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability statusPeter T Campbell, Elizabeth T Jacobs, Cornelia M Ulrich, et al.
Pageof 9